Prostate cancer decisions — 2025

The appeal for service connection for prostate cancer is dismissed as the benefit sought has already been granted in full.

The appeal for service connection for prostate cancer and coronary artery disease, claimed as heart disease, has been withdrawn by the Veteran.

The Board remands the claims for service connection for prostate cancer and erectile dysfunction, including as secondary to exposure to toxic chemicals and burn pits, or alternatively, secondary to a service-connected surgical scar status post prostatectomy associated with prostate cancer.

The Board granted a 20 percent rating for residual voiding dysfunction associated with prostate cancer, effective January 1, 2020.

The Board denied service connection for prostate cancer, finding no competent and probative evidence to support a nexus between the Veteran's cancer and his active duty service or exposure to contaminated water at Camp Lejeune. The Board also denied entitlement to TDIU as there was no evidence of a service-connected disability that precluded substantially gainful employment.

The Board denied service connection for prostate cancer, hypertension, and a gallbladder disability as there is no evidence of current disabilities.

The Board remands the issue of entitlement to service connection for cause of death due to insufficient evidence regarding the Veteran's exposure to herbicide agents and a need for a medical opinion.

The Veteran was denied a TDIU for the period from August 31, 2010, to January 1, 2015, but granted a TDIU for the period from January 1, 2015, to August 16, 2022 (exclusive of the period from September 18, 2017, to December 31, 2017), and was denied special monthly compensation based on housebound status.

The Board remands the claims for service connection for prostate cancer and tinnitus to correct duty to assist errors related to obtaining adequate medical opinions.

The Board granted a 20 percent rating for prostate cancer, effective October 1, 2024, while affirming the reduction of the previous 100 percent rating.

The Board denied service connection for prostate cancer, hypertension, and a gallbladder disability as there is no evidence of current disabilities.

The Board remands the veteran's claims for service connection for various conditions, including rheumatoid arthritis, right hip degenerative joint disease, osteoarthritis, psoriatic arthritis, hypertension, enlarged liver, prostate cancer, diabetes mellitus type II, fever sores, and a compromised immune system, to ensure compliance with prior remand instructions.

The Board remands the claims for service connection for prostate cancer and metastasis of carcinoma of the prostate into the cervical region, to include as due to tactical herbicide exposure, for further development.

The Board granted service connection for residuals of prostate cancer and denied service connection for prostatitis, alopecia areata, and residuals of a hemorrhoidectomy.

The Board granted an effective date of January 21, 2020 for the award of service connection for diabetes mellitus, type II, prostate cancer, erectile dysfunction, and special monthly compensation (SMC) based on loss of use of a creative organ.

The Board denied service connection for prostate cancer, renal failure, and hypertension as there is no evidence linking these conditions to the Veteran's military service or toxic exposure at Camp Lejeune.

The Board dismissed the claims for service connection for left and right upper and lower extremity peripheral neuropathy, glaucoma, as well as erectile dysfunction, vertigo, syncope, fatigue, hypertension, prostate cancer, and a heart disability due to the grant of service connection in an August 2024 rating decision.

The Board remands the issue of entitlement to service connection for prostate cancer due to inadequate consideration of arguments regarding the adequacy of the DTRA's dose estimate.

The Board granted earlier effective dates for service connection and ratings for various conditions, including diabetes mellitus, neuropathy of the lower extremities, and right wrist limited dorsiflexion.

The Board granted service connection for prostate cancer, resolving reasonable doubt in favor of the Veteran and finding credible evidence that he was exposed to herbicide agents during his service near the Korean DMZ.